A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level

被引：7

作者：

Hambali, Nurfarah Lydia ^{[1
]}

Mohd Noh, Malehah ^{[2
]}

Paramasivam, Shahleni ^{[2
]}

Chua, Tock Hing ^{[1
]}

Hayati, Firdaus ^{[3
]}

Payus, Alvin Oliver ^{[2
]}

Tee, Tze Yuan ^{[4
]}

Rosli, Khairul Taufiq ^{[4
]}

Abd Rachman Isnadi, Mohammad Faruq ^{[1
]}

Manin, Benny O. ^{[1
]}

机构：

[1] Univ Malaysia Sabah, Dept Pathobiol & Med Diagnost, Fac Med & Hlth Sci, Kota Kinabalu, Sabah, Malaysia

[2] Univ Malaysia Sabah, Fac Med & Hlth Sci, Med Based Dept, Kota Kinabalu, Sabah, Malaysia

[3] Univ Malaysia Sabah, Fac Med & Hlth Sci, Surg Based Dept, Kota Kinabalu, Sabah, Malaysia

[4] Tawau Hosp, Med Dept, Tawau, Malaysia

来源：

FRONTIERS IN PUBLIC HEALTH | 2020年 / 8卷

关键词：

COVID-19; cytokine release syndrome; IL-6; HBV infection; HCC;

D O I：

10.3389/fpubh.2020.584552

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Interleukin 6 (IL-6) is one of the markers of immune system activation indicating existent infection and inflammation. We present here a case of a 55-year-old male COVID-19 patient with an unusual high level of interleukin 6 (IL-6). Further investigation revealed he had hepatocellular carcinoma (HCC) with underlying hepatitis B. He did not present with respiratory symptoms although a baseline chest x-ray showed changes, and the patient was categorized as Class 3A of COVID-19. Routine investigations proceeded with high-resolution computed tomography and IL-6 to monitor for progression to severe COVID-19. Notably, there was a high IL-6 level but other parameters did not show he was in severe COVID-19. In this report, we conclude that elevated IL-6 level in a COVID-19 patient is not necessarily associated with severe COVID-19.

引用

页数：5

共 9 条

[1] IL-6 Plays a Crucial Role in HBV Infection [J].

Lan, Tian ;

Chang, Lei ;

Wu, Long ;

Yuan, Yu-Feng .

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2015, 3 (04) :271-276

[2] Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? [J].

Liu, Bingwen ;

Li, Min ;

Zhou, Zhiguang ;

Guan, Xuan ;

Xiang, Yufei .

JOURNAL OF AUTOIMMUNITY, 2020, 111

[3] Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages [J].

Merad, Miriam ;

Martin, Jerome C. .

NATURE REVIEWS IMMUNOLOGY, 2020, 20 (06) :355-362

[4] Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review [J].

Ng, Ming-Yen ;

Lee, Elaine Y. P. ;

Yang, Jin ;

Yang, Fangfang ;

Li, Xia ;

Wang, Hongxia ;

Lui, Macy Mei-Sze ;

Lo, Christine Shing-Yen ;

Leung, Barry ;

Khong, Pek-Lan ;

Hui, Christopher Kim-Ming ;

Yuen, Kwok-Yung ;

Kuo, Michael D. .

RADIOLOGY-CARDIOTHORACIC IMAGING, 2020, 2 (01)

[5]

Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337, DOI 10.55563/clinexprheumatol/xcdary

[6] Rethinking interleukin-6 blockade for treatment of COVID-19 [J].

Scherger, S. ;

Henao-Martinez, A. ;

Franco-Paredes, C. ;

Shapiro, L. .

MEDICAL HYPOTHESES, 2020, 144

[7] Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis [J].

Shakiba, Ebrahim ;

Ramezani, Mazaher ;

Sadeghi, Masoud .

CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2018, 4 (03) :182-190

[8] Involvement of Interleukin 6 in Hepatitis B Viral Infection [J].

Xia, Caixia ;

Liu, Yanning ;

Chen, Zhi ;

Zheng, Min .

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2015, 37 (02) :677-686

[9] Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality [J].

Zhang, Chi ;

Wu, Zhao ;

Li, Jia-Wen ;

Zhao, Hong ;

Wang, Gui-Qiang .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)

← 1 →